Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis (GLUSENTIC)

Glucagon is secreted from pancreatic alpha-cells in response to protein-rich meals and during hypoglycemia. A physiological feedback system exists between the liver and the pancreatic alpha cells termed the liver-alpha cell axis and signifies the role between amino acid-stimulated glucagon secretion and glucagon-stimulated amino acid metabolism.

Individuals with non-alcoholic fatty liver disease have increased levels of glucagon (hyperglucagonemia) and amino acids (hyperaminoacidemia), which suggests that hepatic steatosis may uncouple glucagon's effect on amino acid metabolism (i.e. reduced glucagon sensitivity). Since hyperglucagonemia contributes to diabetes progression - due to its potentiating effects on hepatic glucose production - hepatic steatosis may create a diabetogenic circle. This study aims to develop and evaluate a test for measuring glucagon sensitivity in humans.

The investigators (Associate Prof. Nicolai J Wewer Albrechtsen and Prof. Jørgen Rungby) will investigate whether amino acid metabolism is attenuated in individuals with hepatic steatosis (assessed by magnetic resonance imaging) due to impaired hepatic glucagon sensitivity and if glucagon's effect on hepatic glucose production is intact compared to individuals without hepatic steatosis suggestive of biased signaling.

Study Overview

• Status: Completed
• Conditions: Obesity; Type 1 Diabetes; Non-Alcoholic Fatty Liver Disease; Glucagon Resistance
• Intervention / Treatment: Diagnostic test: Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon

Detailed Description

Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (long-term) and non- transcriptional (acute) mechanisms. Several groups including the investigators have linked glucagon secretion to hepatic amino acid metabolism suggesting a mutual feedback cycle, termed the liver-alpha cell axis. A disruption of this axis, which has been shown both pharmacologically using glucagon receptor antagonists and genetically in glucagon receptor knockout mouse models, leads to increased glucagon (hyperglucagonemia) and amino acid (hyperaminoacidemia) concentrations. This phenotype is also evident in subjects with biopsy-verified metabolic dysfunction-associated steatotic liver disease (MASLD) independent of type 2 diabetes suggesting reduced hepatic glucagon sensitivity in the presence of hepatic steatosis. Glucagon increases amino acid catabolism by potentiating ureagenesis, a pathway exclusive to the liver, and hepatic accumulation of triglycerides may reduce glucagon's ability to augment amino acid turnover. Some amino acids are more potent in stimulating glucagon secretion (glucagonotropic amino acids), including alanine, and the glucagon-alanine index is currently used as a surrogate marker for the hepatic actions of glucagon on ureagenesis. The fate of amino acid turnover depends on both glucagon and insulin dynamics by stimulating amino acid catabolism and synthesis, respectively. Studying the effects of glucagon in individuals with type 1 diabetes will allow one to differentiate between the combined effects of glucagon and insulin compared to the effects of glucagon alone.

This study aims to explore hepatic glucagon sensitivity towards amino acid metabolism in individuals with and without hepatic steatosis (based on magnetic resonance imaging (MRI)).

The investigators hypothesize that the effect of endogenous and exogenous glucagon on plasma amino acid levels are impaired in individuals with MASLD (based on hepatic steatosis measured by MRI) compared to controls.

The nomenclature for MASLD has recently been updated from non-alcoholic fatty liver disease (NAFLD) (https://pubmed.ncbi.nlm.nih.gov/37363821/).

• Study Type: Interventional
• Enrollment (Actual): 65
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nicolai J Wewer Albrechtsen; Phone Number: 21700880; Email: nicolai.albrechtsen@sund.ku.dk
• Study Contact Backup: Name: Sasha A S Kjeldsen; Phone Number: 50871715; Email: sasha.kjeldsen@sund.ku.dk

Study Locations

• Denmark
  • Copenhagen, Denmark
    • Bispebjerg University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Group 1 (lean controls)

Inclusion Criteria:

• BMI = 18.6-25 kg/m2
• Male or female
• 25-65 years of age

Exclusion Criteria:

• Diabetes (ADA criteria)
• Significant alcohol/drug abuse as per investigators judgement
• Amino acid-related diseases such as phenylketonuria
• Kidney disease
• Cardiac problems
• Cancer within the past 1 year
• Severe claustrophobia
• Pacemaker or other non-MR-compatible devices
• Pregnancy or breastfeeding.
• Fib4 score > 3.25.
• Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol

Group 2 (overweight and obese individuals)

Inclusion Criteria:

• BMI = 25-40 kg/m2
• Male or female
• 25-65 years of age

Exclusion Criteria:

• Diabetes (ADA criteria)
• Significant alcohol/drug abuse as per investigators judgement
• Amino acid-related diseases such as phenylketonuria
• Kidney disease
• Cardiac problems
• Cancer within the past 1 year
• Severe claustrophobia
• Pacemaker or other non-MR-compatible devices
• Pregnancy or breastfeeding
• Abdominal diameter >70 cm
• Fib4 score > 3.25.
• Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol

Group 3 (individuals with type 1 diabetes)

Inclusion Criteria:

• BMI = 18.6-40 kg/m2
• Male or female
• C-peptide negative
• Insulin pump user
• 25-65 years of age

Exclusion Criteria:

• Type 2 diabetes
• Closed loop user
• Microalbuminuria (30-300 mg/g)
• Significant alcohol/drug abuse as per investigators judgement
• Amino acid-related diseases such as phenylketonuria
• Kidney disease
• Cardiac problems
• Cancer within the past 1 year
• Severe claustrophobia
• Pacemaker or other non-MR-compatible devices
• Pregnancy or breastfeeding
• Abdominal diameter >70 cm
• Fib4 score > 3.25.
• Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol

Following inclusion and study completion, our two groups of lean individuals (n=20) and overweight and obese individuals (n=30) will be stratified into two groups based on liver fat content assessed by the magnetic resonance imaging scan. Individuals with <5.6% hepatic steatosis will be allocated to the control group and individuals with ≥5.6% hepatic steatosis to the MASLD group.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Measuring glucagon sensitivity in humans; Participants will be subjected to two experimental days.

Diagnostic test: Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon; The test consists of two experimental study days: Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes. Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes. All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition. Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with <5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in the calculated GLUSENTIC index between individuals with or without MASLD without diabetes	This index is conceptually be based on the Matsuda/composite index, and will factor in fasting and amino acid-stimulated levels of glucagon and total amino acids using the following formula: 100/(SQRT(Fasting plasma amino acids levels (mean at time -10 and 0 minutes) * Fasting plasma glucagon levels (mean at time -10 and 0 minutes) * Amino acid-stimulated amino acid levels (mean at time 40 and 45 minutes) * Amino acid-stimulated glucagon levels (mean at time 40 and 45 minutes)).	Time from the first blood sample (at time -10 minutes, following an overnight fast) until the amino acid infusion stops (45 minutes)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Simple linear regression between hepatic steatosis (%) and the GLUSENTIC index	Measurements of hepatic steatosis will be assessed by magnetic resonance imaging. Data from controls and MASLD without diabetes will be included.	Time from the first blood sample (at time -10 minutes, following an overnight fast) until the amino acid infusion stops (45 minutes)
ROC curve analysis to evaluate cut-off value for GLUSENTIC index	Controls and MASLD groups will be included.	Time from the first blood sample (at time -10 minutes, following an overnight fast) until the amino acid infusion stops (45 minutes)
Differences in the glucagon-alanine index	The glucagon-alanine index will be measured as previously described: https://pubmed.ncbi.nlm.nih.gov/29305624/. Measurements of hepatic steatosis will be assessed by magnetic resonance imaging. Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	The index will be measured on samples collected after an overnight fast (12 hours)
Differences in plasma levels of amino acids during the amino acid tolerance test (determined by baseline corrected AUC)	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the start of infusion (0 minutes) until time 60 minutes.
Glucagon's ability (exogenous glucagon) to increase amino acid disappearance (determined by baseline corrected AUC or delta) for total amino acid levels and the individual amino acids.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the glucagon injection (time 0 minutes) until time 20 minutes.
Differences in plasma levels of total amino acids and alanine following an overnight fast.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Measured on samples collected after an overnight fast (12 hours)
Baseline corrected AUC for glucagon after a bolus injection of glucagon.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for glucagon during and after the amino acid tolerance test.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made. For insulin and C-peptide measurements, only individuals without diabetes will be compared.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Differences in plasma levels of glucagon following an overnight fast.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Measured on samples collected after an overnight fast (12 hours)
Baseline corrected AUC for glucose after a bolus injection of glucagon.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for insulin after a bolus injection of glucagon.	Comparisons between controls and MASLD will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for C-peptide after a bolus injection of glucagon.	Comparisons between controls and MASLD will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for urea after a bolus injection of glucagon.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for triglycerides after a bolus injection of glucagon.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the glucagon injection (time 0 minutes) until time 120 minutes.
Baseline corrected AUC for glucose during and after the amino acid tolerance test.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Baseline corrected AUC for insulin during and after the amino acid tolerance test.	Comparisons between controls and MASLD will be made.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Baseline corrected AUC for C-peptide during and after the amino acid tolerance test.	Comparisons between controls and MASLD and will be made.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Baseline corrected AUC for urea during and after the amino acid tolerance test.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Baseline corrected AUC for triglycerides during and after the amino acid tolerance test.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the amino acid infusion starts (time 0 minutes) until time 180 minutes.
Differences in the formula (plasma urea/plasma amino acids) after the amino acid tolerance test.	Comparisons between controls, MASLD and individuals with type 1 diabetes will be made.	Time from the amino acid infusion stops (time 45 minutes) until time 180 minutes.
Differences in total and individual amino acids between individuals with overweight or obesity without hepatic steatosis who have been BMI-matched to individuals with hepatic steatosis.	Baseline subtracted AUCs will be made and individuals with or without MASLD, who are matched on BMI in a 1:2 ratio will be compared.	Time 0-120 minutes on the day of the glucagon injection and time 0-180 minutes on the day of the amino acid tolerance test.
Differences in glucagon between individuals with overweight or obesity without hepatic steatosis who have been BMI-matched to individuals with hepatic steatosis.	Baseline subtracted AUCs will be made and individuals with or without MASLD, who are matched on BMI in a 1:2 ratio will be compared.	Time time 0-180 minutes on the day of the amino acid tolerance test.
Simple linear regression between the variables, pancreatic steatosis and amino acid stimulated glucagon or insulin levels in individuals without diabetes.	Data from controls and MASLD will be included.	Pancreatic steatosis and time point 30 minutes on the day of the amino acid tolerance test will be used.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in FGF-21	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minuteson the day of the amino acid infusion.
Differences in GLP-1	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minutes on the day of the amino acid infusion.
Differences in GIP	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minutes on the day of the amino acid infusion.
Differences in GDF-15	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minutes on the day of the amino acid infusion.
Differences in focused genotyping (PNPLA3; MBOAT7; GCKR; TNF; TM6SF2).	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minutes on the day of the amino acid infusion.
Differences in follistatin	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minuteson the day of the amino acid infusion.
Differences in fetuin-B	Comparisons between controls, individuals with hepatic steatosis and individuals with type 1 diabetes will be made.	From time -10 to 120 minutes on the day of the glucagon bolus infusion and from time -10 to 180 minuteson the day of the amino acid infusion.

Collaborators and Investigators

• Sponsor: University of Copenhagen
• Collaborators: Rigshospitalet, Denmark; Bispebjerg Hospital

Publications and helpful links

Helpful Links

• review of the litterature

Study record dates

Study Major Dates

• Study Start (Actual): May 27, 2021
• Primary Completion (Actual): October 21, 2023
• Study Completion (Actual): October 21, 2023

Study Registration Dates

• First Submitted: May 17, 2021
• First Submitted That Met QC Criteria: May 28, 2021
• First Posted (Actual): June 1, 2021

Study Record Updates

• Last Update Posted (Actual): October 24, 2023
• Last Update Submitted That Met QC Criteria: October 21, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Physiological Effects of Drugs; Gastrointestinal Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; Glucagon; Glucagon-Like Peptide 1
• Other Study ID Numbers: GLUSENTIC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: We have not decided to share IPD as this also would require approval from the ethical and data approval comitee.

Study Data/Documents

1. Statistical Analysis Plan

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No